270 related articles for article (PubMed ID: 32096887)
41. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
Rogers KA; Jones JA
Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
[TBL] [Abstract][Full Text] [Related]
43. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
44. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Morabito F; Gentile M; Seymour JF; Polliack A
Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
[TBL] [Abstract][Full Text] [Related]
45. Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials.
Vidal L; Gurion R; Ram R; Raanani P; Bairey O; Robak T; Gafter-Gvili A; Shpilberg O
Leuk Lymphoma; 2016 Sep; 57(9):2047-57. PubMed ID: 26980554
[TBL] [Abstract][Full Text] [Related]
46. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
Jaksic B; Brugiatelli M; Krc I; Losonczi H; Holowiecki J; Planinc-Peraica A; Kusec R; Morabito F; Iacopino P; Lutz D
Cancer; 1997 Jun; 79(11):2107-14. PubMed ID: 9179056
[TBL] [Abstract][Full Text] [Related]
47. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Novak J; Strugov V; Gill D; Gribben JG; Kwei K; Dai S; Hsu E; Dean JP; Flinn IW
Haematologica; 2022 Sep; 107(9):2108-2120. PubMed ID: 35021599
[TBL] [Abstract][Full Text] [Related]
48. Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.
Tam C; Kuss B; Opat S; Boulos J; Marlton P
Intern Med J; 2017 Jul; 47 Suppl 4():5-10. PubMed ID: 28685928
[TBL] [Abstract][Full Text] [Related]
49. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
50. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
51. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
[TBL] [Abstract][Full Text] [Related]
52. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.
Foà R; Del Giudice I; Cuneo A; Del Poeta G; Ciolli S; Di Raimondo F; Lauria F; Cencini E; Rigolin GM; Cortelezzi A; Nobile F; Callea V; Brugiatelli M; Massaia M; Molica S; Trentin L; Rizzi R; Specchia G; Di Serio F; Orsucci L; Ambrosetti A; Montillo M; Zinzani PL; Ferrara F; Morabito F; Mura MA; Soriani S; Peragine N; Tavolaro S; Bonina S; Marinelli M; De Propris MS; Starza ID; Piciocchi A; Alietti A; Runggaldier EJ; Gamba E; Mauro FR; Chiaretti S; Guarini A
Am J Hematol; 2014 May; 89(5):480-6. PubMed ID: 24415640
[TBL] [Abstract][Full Text] [Related]
53. A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada.
Chatterjee A; van de Wetering G; Goeree R; Owen C; Desbois AM; Barakat S; Manzoor BS; Sail K
Pharmacoecon Open; 2023 Mar; 7(2):199-216. PubMed ID: 36334238
[TBL] [Abstract][Full Text] [Related]
54. Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves.
Alrawashdh N; Persky DO; McBride A; Sweasy J; Erstad B; Abraham I
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e820-e831. PubMed ID: 34274291
[TBL] [Abstract][Full Text] [Related]
55. Chlorambucil plus theophylline vs chlorambucil alone as a front line therapy for B-cell chronic lymphatic leukemia.
Mabed M; Aref S; Fouda M; El-Sharawy S
Leuk Lymphoma; 2004 Oct; 45(10):2029-35. PubMed ID: 15370247
[TBL] [Abstract][Full Text] [Related]
56. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
[TBL] [Abstract][Full Text] [Related]
57. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Cramer P; Langerbeins P; Eichhorst B; Hallek M
Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
[TBL] [Abstract][Full Text] [Related]
58. Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.
Innocenti I; Autore F; Pasquale R; Morelli F; Efremov DG; Laurenti L
Expert Rev Hematol; 2017 Dec; 10(12):1069-1076. PubMed ID: 29082795
[TBL] [Abstract][Full Text] [Related]
59. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Mato AR; Roeker LE; Allan JN; Pagel JM; Brander DM; Hill BT; Cheson BD; Furman RR; Lamanna N; Tam CS; Handunnetti S; Jacobs R; Lansigan F; Bhavsar E; Barr PM; Shadman M; Skarbnik AP; Goy A; Beach DF; Svoboda J; Pu JJ; Sehgal AR; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Rhodes J; Ujjani CS; Nabhan C
Am J Hematol; 2018 Nov; 93(11):1394-1401. PubMed ID: 30132965
[TBL] [Abstract][Full Text] [Related]
60. Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
Sinha R; Redekop WK
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e131-e142. PubMed ID: 29398648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
